Robert A ORourke
Overview
Explore the profile of Robert A ORourke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
4137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Acharjee S, Teo K, Jacobs A, Hartigan P, Barn K, Gosselin G, et al.
Am Heart J
. 2016 Feb;
173:108-17.
PMID: 26920603
Objectives: To determine whether sex-based differences exist in clinical effectiveness of percutaneous coronary intervention (PCI) when added to optimal medical therapy (OMT) in patients with stable coronary artery disease. Background:...
2.
Shaw L, Weintraub W, Maron D, Hartigan P, Hachamovitch R, Min J, et al.
Am Heart J
. 2012 Aug;
164(2):243-50.
PMID: 22877811
Background: The COURAGE trial reported similar clinical outcomes for patients with stable ischemic heart disease (SIHD) receiving optimal medical therapy (OMT) with or without percutaneous coronary intervention (PCI). The current...
3.
Gosselin G, Teo K, Tanguay J, Gokhale R, Hartigan P, Maron D, et al.
Am J Cardiol
. 2012 Mar;
109(7):954-9.
PMID: 22445578
Previous studies have suggested that percutaneous coronary intervention (PCI) decreases long-term mortality in patients with silent myocardial ischemia (SMI), but whether PCI specifically decreases mortality when added to intensive medical...
4.
Mancini G, Hartigan P, Bates E, Sedlis S, Maron D, Spertus J, et al.
Circ Cardiovasc Interv
. 2011 Nov;
4(6):545-52.
PMID: 22045968
Background: The extent to which recurrent events in patients with stable coronary artery disease is attributable to progression of an index lesion originally ≥50% diameter stenosis (DS) but not revascularized...
5.
Maron D, Boden W, Spertus J, Hartigan P, Mancini G, Sedlis S, et al.
J Am Coll Cardiol
. 2011 Jul;
58(2):131-7.
PMID: 21718908
Objectives: Our purpose was to clarify the clinical utility of identifying metabolic syndrome (MetS) in patients with coronary artery disease (CAD). Background: It is uncertain whether MetS influences prognosis in...
6.
Zhang Z, Kolm P, Boden W, Hartigan P, Maron D, Spertus J, et al.
Circ Cardiovasc Qual Outcomes
. 2011 Feb;
4(2):172-82.
PMID: 21304091
Background: The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial compared percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT) to OMT alone in reducing the risk of...
7.
Maron D, Boden W, Weintraub W, Calfas K, ORourke R
Curr Treat Options Cardiovasc Med
. 2010 Dec;
13(1):16-25.
PMID: 21120640
Medical therapy is the foundation upon which all treatment for patients with stable coronary artery disease (CAD) is based, regardless of whether revascularization is performed. Although professional societies recommend comprehensive...
8.
Chaitman B, Hartigan P, Booth D, Teo K, Mancini G, Kostuk W, et al.
Circ Cardiovasc Qual Outcomes
. 2010 Jul;
3(5):476-83.
PMID: 20664026
Background: The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial enrolled patients from 3 distinct healthcare systems (HCSs) in North America. The primary aim of this study was...
9.
ORourke R
Curr Probl Cardiol
. 2010 Jul;
35(8):384-446.
PMID: 20620570
The classification of patients with angina pectoris into various subgroups, which clearly differ in risk based on the patient's characteristics, is difficult. Changes in pain threshold occur frequently. The variation...
10.
Maron D, Boden W, ORourke R, Hartigan P, Calfas K, Mancini G, et al.
J Am Coll Cardiol
. 2010 Mar;
55(13):1348-58.
PMID: 20338496
Objectives: This paper describes the medical therapy used in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial and its effect on risk factors. Background: Most cardiovascular clinical...